After several unsuccessful treatments, Barbara Marty and Manuel Schibli's cancer has disappeared. This was made possible by innovative therapies based on molecular analysis of the tumor.
When Barbara Marty was diagnosed with lung cancer five years ago, she was hardly surprised. “I knew the dangers, they were on every packet,” says the now 67-year-old former smoker. But she is certain: “I’ll get through this.” As a former professional politician, Marty is used to fighting. But cancer was to become her toughest opponent: after an extremely stressful course of chemotherapy and immunotherapy, it has been pushed back. But not defeated. When she finally stops the treatment after more than two years and wants to return to work, she receives good and bad news: there are only a few metastases on her lungs. Instead, the lymph channels are now affected.
Today, cancer research knows that every tumor is different. The more precisely it can be analyzed, the sooner a targeted and therefore effective therapy is possible. “We are getting better and better at recognizing the differences in the molecular profile of tumours,” says Professor Markus Manz, Director of the Department of Medical Oncology and Haematology at the University Hospital Zurich and Head of the Comprehensive Center Zurich (see box). “Ideally, we find individual therapies that are not only efficient, but also minimize side effects.”
Marty’s molecular tumor profile showed a mutation in the KRAS gene. At that time, an international study with a new type of drug called AMG 510 was being conducted precisely for such patients. “A stroke of luck for me,” says Marty, who agreed to take part and has since been taking eight tablets a day, having regular blood tests and CT scans. And lo and behold: the cancer has virtually disappeared to this day. “Doctors who don’t know my history don’t believe that I’ve ever had cancer,” she says. What’s more, the therapy has no side effects for her.
